Healthcare
Live Price
Offline$15.37
-2.29% today
1Y Change
+86.21%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viatris Inc. (VTRS) is a Healthcare stock with a market cap of $17.70B and listed on NASDAQ. The stock last traded around $15.37 and up 86.2% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -3.0%, EPS growth of -466.0%, a dividend yield of 3.2%. What stands out right now is revenue -3.0%, EPS -466.0%, free cash flow -2.0% with operating margin -18.6% and ROIC -7.9%. The dividend matters to the case here, with a current yield around 3.2%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VTRS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTRS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VTRS Max Drawdown
-19.65%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VTRS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$17.9B
+10.0% YoY
FY Net Income
-$1.3B
-161.1% YoY
Free Cash Flow
$2.5B
-0.1% YoY
Revenue Growth
-3.0%
EPS Growth
-466.0%
Gross Margin
35.1%
Net Margin
-24.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 14.3B | 14.7B | 15.4B | 16.3B | 17.9B |
| Gross Profit | 5.0B | 5.6B | 6.4B | 6.5B | 5.6B |
| Operating Income | -2.7B | 10M | 766M | 1.6B | -34M |
| EBITDA | -395M | 2.8B | 3.5B | 6.4B | 4.5B |
| Net Income | -3.5B | -634M | 55M | 2.1B | -1.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.3B | 735M | 992M | 1.3B | 701M |
| Total Assets | 37.2B | 41.5B | 47.7B | 50.0B | 54.8B |
| Total Liabilities | 22.5B | 22.9B | 27.2B | 28.9B | 34.4B |
| Shareholder Equity | 14.7B | 18.6B | 20.5B | 21.1B | 20.5B |
| Total Debt | 14.7B | 14.3B | 18.4B | 19.5B | 23.4B |
| Net Debt | 13.4B | 13.6B | 17.4B | 18.3B | 22.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3.0B
+0.6% YoY
Capital Expenditures
509M
-4.1% YoY
Free Cash Flow
2.5B
-0.1% YoY
Key ratios
Gross Margin
35.1%
Operating Margin
-18.6%
Net Margin
-24.6%
ROE
-23.0%
Debt / Equity
1.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.